Keros Therapeutics, Inc. (KROS) – What Are Investment Firms Thinking About This Stock?

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given a consensus recommendation of “Hold” by the nine brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $20.50.

Several brokerages recently issued reports on KROS. Zacks Research upgraded Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Wells Fargo & Company decreased their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Wall Street Zen downgraded Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 24th. Finally, Leerink Partners lowered their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 4th.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $11.61 on Friday. The firm has a market cap of $230.23 million, a PE ratio of -3.14 and a beta of 1.12. Keros Therapeutics has a one year low of $9.69 and a one year high of $22.55. The firm’s fifty day moving average is $11.27 and its two-hundred day moving average is $12.22.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. Research analysts predict that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics announced that its board has approved a stock buyback program on Wednesday, September 9th that authorizes the company to repurchase $5 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.3% of its shares through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Keros Therapeutics

In related news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total transaction of $36,714.72. Following the completion of the sale, the insider directly owned 27,559 shares of the company’s stock, valued at $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,343 shares of company stock worth $54,985 over the last three months. 12.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Keros Therapeutics in the second quarter valued at about $29,898,000. Nantahala Capital Management LLC purchased a new position in Keros Therapeutics in the second quarter valued at about $15,091,483. Dimensional Fund Advisors LP increased its holdings in Keros Therapeutics by 453.9% in the first quarter. Dimensional Fund Advisors LP now owns 321,360 shares of the company’s stock valued at $3,547,000 after buying an additional 263,347 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Keros Therapeutics during the 2nd quarter valued at approximately $2,641,000. Finally, Man Group plc acquired a new stake in shares of Keros Therapeutics during the 2nd quarter valued at approximately $1,664,000. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-?) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.